Sinopharm Group Co Ltd
OTC:SHTDY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sinopharm Group Co Ltd
OTC:SHTDY
|
CN |
|
G
|
Gilead Sciences Inc
BMV:GILD
|
US |
|
S
|
Sofina SA
SWB:8FS
|
BE |
|
A
|
Amgen Inc
BMV:AMGN
|
US |
|
T
|
Tokio Marine Holdings Inc
OTC:TKOMY
|
JP |
|
Dillard's Inc
NYSE:DDS
|
US |
Wall St Price Targets
SHTDY Price Targets Summary
Sinopharm Group Co Ltd
According to Wall Street analysts, the average 1-year price target for
SHTDY is 14.58 USD with a low forecast of 10.85 USD and a high forecast of 17.9 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is SHTDY's stock price target?
Price Target
14.58
USD
According to Wall Street analysts, the average 1-year price target for
SHTDY is 14.58 USD with a low forecast of 10.85 USD and a high forecast of 17.9 USD.
What is the Revenue forecast for Sinopharm Group Co Ltd?
Projected CAGR
5%
Over the last 14 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 3 years is 5%.
What is the Gross Profit forecast for Sinopharm Group Co Ltd?
Projected CAGR
9%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 12%. The projected CAGR for the next 3 years is 9%.
What is the Operating Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
26%
Over the last 14 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 3 years is 26%.
What is the Pre-Tax Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
10%
Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 12%. The projected CAGR for the next 3 years is 10%.
What is the Net Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
10%
Over the last 14 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 10%.